A clinician's guide to statin drug-drug interactions

Journal of Clinical Lipidology

Volumn 8, Issue 3 SUPPL, 2014, Pages

  Kellick, Kenneth A ^a,b   Bottorff, Michael ^c   Toth, Peter P ^d,e  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c USA   (United States)

^d Medical Center   (United States)

^e UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Cytochrome; Drug drug interactions; Glucuronidation; Pharmacogenetics; Pharmacokinetics; Statins

Indexed keywords

AMIODARONE; ATORVASTATIN; CERIVASTATIN; CLARITHROMYCIN; CYCLOSPORIN; DILTIAZEM; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FLUCONAZOLE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LIVER ENZYME; LOPINAVIR PLUS RITONAVIR; MEVINOLIN; NELFINAVIR; NICOTINIC ACID; NON PRESCRIPTION DRUG; PITAVASTATIN; POSACONAZOLE; PRAVASTATIN; PRESCRIPTION DRUG; PROPRANOLOL; RANOLAZINE; ROSUVASTATIN; SIMVASTATIN; TELITHROMYCIN; UNINDEXED DRUG; VERAPAMIL; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTIVIRUS AGENT; CYTOCHROME P450; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN; TUMOR PROTEIN;

AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR RISK; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; ENZYME BLOOD LEVEL; ENZYME POLYMORPHISM; HUMAN; MYALGIA; MYOPATHY; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; AGE; ALLELE; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CHEMISTRY; DRUG INTERACTION; ETHNOLOGY; EVIDENCE BASED MEDICINE; GENETICS; METABOLISM; MUSCULAR DISEASES; PRACTICE GUIDELINE; RECEIVER OPERATING CHARACTERISTIC;

AGE FACTORS; ALLELES; ANTIVIRAL AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; ATP-BINDING CASSETTE TRANSPORTERS; CARDIOVASCULAR DISEASES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; MYALGIA; NEOPLASM PROTEINS; NONPRESCRIPTION DRUGS; ORGANIC ANION TRANSPORTERS; ROC CURVE;

EID: 84899794579     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2014.02.010     Document Type: Article

References (47)

1. P. Gazzerro, M.C. Proto, and G. Gangemi et al. Pharmacological actions of statins: a critical appraisal in the management of cancer Pharmacol Rev 64 2012 102 146
2. M. Niemi, M.K. Pasanen, and P.J. Neuvonen Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake Pharmacol Rev 63 2011 157 181
3. C.R. Harper, and T.A. Jacobson Avoiding statin myopathy: understanding key drug interactions Clin Lipidol 6 2011 665 674
4. International Transporter Consortium K.M. Giacomini, S.M. Huang, and D.J. Tweedie et al. Membrane transporters in drug development Nat Rev Drug Discov 9 2010 215 236
5. M. Niemi Transporter pharmacogenetics and statin toxicity Clin Pharmacol Ther 87 2010 130 133
6. B.A. Golomb, and M.A. Evans Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism Am J Cardiovasc Drugs 8 2008 373 418
7. K.M. Ho, and S.W. Walker Statins and their interactions with other lipid-modifying medications Ther Adv in Drug Safe 3 2012 35 46
8. R. Elsby, C. Hilgendorf, and K. Fenner Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1 Clin Pharmacol Ther 92 2012 584 598
9. C.W. Holtzman, B.S. Wiggins, and S.A. Spinler Role of P-glycoprotein in statin drug interactions Pharmacotherapy 26 2006 1601 1607
10. SEARCH Collaborative Group E. Link, S. Parish, and J. Armitage et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study N Engl J Med 359 2008 789 799
11. P.J. Neuvonen, M. Niemi, and J.T. Backman Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance Clin Pharmacol Ther 80 2006 565 581
12. T.R. Joy, and R.A. Hegele Narrative review: statin-related myopathy Ann Intern Med 150 2009 858 868
13. A. Corsini, S. Bellosta, R. Baetta, R. Fumagalli, R. Paoletti, and F. Bernini New insights into the pharmacodynamic and pharmacokinetic properties of statins Pharmacol Ther 84 1999 413 428
14. D.E. Cohen, F.A. Anania, and N. Chalasani National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists Am J Cardiol 97 2006 77C 81C
15. D.I. Chasman, D. Posada, L. Subrahmanyan, N.R. Cook, V.P. Stanton Jr., and P.M. Ridker Pharmacogenetic study of statin therapy and cholesterol reduction JAMA 291 2004 2821 2827
16. S. Bellosta, R. Paoletti, and A. Corsini Safety of statins: focus on clinical pharmacokinetics and drug interactions Circulation 109 2004 III50 III57
17. A.D. Rodriques Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the "rank order" approach Drug Metabolism Letters 1 2007 31 35
18. US Food and Drug Administration. FDA Online Label Repository. Available at: http://labels.fda.gov/. Accessed February 9, 2014.
19. US Food and Drug Administration. FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Available at: http://www.fda.gov/Drugs/ DrugSafety/ucm256581.htm. Accessed February 8, 2014.
20. US Food and Drug Administration. FDA Drug Safety Communication: Revised dose limitation for Zocor (simvastatin) when taken with amiodarone. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm283137.htm. Accessed February 8, 2014.
21. US Food and Drug Administration. FDA Drug Safety Communication: FDA announces safety changes in labeling for some cholesterol-lowering drugs. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Accessed February 8, 2014.
22. Merck & Co. Inc. ZOCOR (simvastatin) tablets prescribing information. Available at: http://www.merck.com/product/usa/pi-circulars/z/zocor/zocor-pi. pdf. Accessed February 8, 2014.
23. Parke-Davis-Pfizer. Lipitor (atorvastatin calcium) tablets for oral administration prescribing information. Available at: http://labeling.pfizer. com/ShowLabeling.aspx?id=587. Accessed February 8, 2014.
24. AstraZeneca. Crestor (rosuvastatin calcium) tablets prescribing information. Available at: http://www1.astrazeneca-us.com/pi/crestor.pdf. Accessed February 8, 2014.
25. Kowa Pharmaceuticals America I. LIVALO (pitavastatin) tablet 1 mg, 2 mg, and 4 mg package insert - product labeling. Available at: http://www.kowapharma. com/documents/LIVALO-PI-CURRENT.pdf. Accessed February 8, 2014.
26. Merck & Co. Inc. MEVACOR (lovastatin) tablets. Available at: http://www.merck.com/product/usa/pi-circulars/m/mevacor/mevacor-pi.pdf. Accessed February 9, 2014.
27. Novartis Pharmaceuticals Corporation. Lescol (fluvastatin sodium) capsules/Lescol XL (fluvastatin sodium) extended-release tablets for oral use prescribing information. Available at: https://www.pharma.us.novartis.com/ product/pi/pdf/Lescol.pdf. Accessed February 9, 2014.
28. Company B-MS. PRAVACHOL (pravastatin sodium) tablets. Available at: http://packageinserts.bms.com/pi/pi-pravachol.pdf. Accessed February 9, 2014.
29. Elsevier/Gold Standard Inc. Clinical Pharmacology [database online]. Available at: http://www.goldstandard.com/product/gold-standard-drug-database. Accessed November, 2013.
30. P.J. Neuvonen, T. Kantola, and K.T. Kivisto Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole Clin Pharmacol Ther 63 1998 332 341
31. T. Kantola, K.T. Kivisto, and P.J. Neuvonen Effect of itraconazole on the pharmacokinetics of atorvastatin Clin Pharmacol Ther 64 1998 58 65
32. N.J. Stone, J. Robinson, and A.H. Lichtenstein et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [e-pub ahead of print] J Am Coll Cardiol 2013 10.1016/j.jacc.2013.11.002 Accessed March 14, 2014
33. T.A. Jacobson Overcoming 'ageism' bias in the treatment of hypercholesterolaemia: a review of safety issues with statins in the elderly Drug Saf 29 2006 421 448
34. A.J. McLean, and D.G. Le Couteur Aging biology and geriatric clinical pharmacology Pharmacol Rev 56 2004 163 184
35. K.S. Nair Aging muscle Am J Clin Nutr 81 2005 953 963
36. A. Parkinson, D.R. Mudra, C. Johnson, A. Dwyer, and K.M. Carroll The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes Toxicol Appl Pharmacol 199 2004 193 209
37. US Food and Drug Administration. FDA Drug Safety Communication: ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm204882.htm. Accessed February 9, 2014.
38. US Food and Drug Administration. FDA Drug Safety Communication: interaction between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm293877.htm. Accessed February 9, 2014.
39. US Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at: http://aidsinfo.nih.gov/guidelines#. Accessed November 2013.
40. M.D. Weltman, G.C. Farrell, P. Hall, M. Ingelman-Sundberg, and C. Liddle Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis Hepatology 27 1998 128 133
41. C.C. Vere, C.T. Streba, L. Streba, and I. Rogoveanu Statins in the treatment of hepatitis C Hepat Mon 12 2012 369 371
42. S. Tandra, and R. Vuppalanchi Use of statins in patients with liver disease Curr Treat Options Cardiovasc Med 11 2009 272 278
43. K.G. Tolman The liver and lovastatin Am J Cardiol 89 2002 1374 1380
44. E.A. Stein Statins and children: whom do we treat and when? Circulation 116 2007 594 595
45. N. Lamaida, E. Capuano, L. Pinto, E. Capuano, R. Capuano, and V. Capuano The safety of statins in children Acta Paediatr 102 2013 857 862
46. National Kidney Foundation Inc. NFK KDOQI Guidelines. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Available at: http://www.kidney.org/professionals/kdoqi/ guideline-diabetes/guide4.htm. Accessed February 9, 2014.
47. Sandoz Canada I. Sandoz Lovastatin. Lovastatin Tablets USP Consumer Information. Available at: http://www.sandoz.ca/cs/groups/public/documents/ document/n-prod-905330.pdf. Accessed February 9, 2014.